Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: A pilot study

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 2, 2002, Pages 687-690

  Lampit, Meir ^a   Golander, Avraham ^b   Guttmann, Hadassah ^b   Hochberg, ZE'Ev ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Dana Children's Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GONADORELIN AGONIST; GONADOTROPIN; TRIPTORELIN;

AGE; ARTICLE; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; GROWTH RATE; GROWTH RETARDATION; HORMONE INHIBITION; HUMAN; PILOT STUDY; PRECOCIOUS PUBERTY; PRIORITY JOURNAL;

EQUIDAE;

EID: 0036172498     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.2.8242     Document Type: Article

References (17)

1. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function
2. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years
3. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment. French study group of Decapeptyl in precocious puberty
4. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years
5. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty
6. Growth velocity and serum aminoterminal propeptide of type III procollagen in precocious puberty during gonadotropin-releasing hormone analogue treatment
7. Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty
8. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist
9. The role of estrogen in bone growth and maturation during childhood and adolescence
10. Short term, low dose estradiol accelerates ulnar growth in boys
11. Treatment of familial male precocious puberty with spironolactone and testolactone
12. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay
13. Comparison of pharmacodynamic properties of various estrogen formulations
14. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
15. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom)
16. Use of estrogen in young girls with Turner syndrome: Effects on memory
17. Choosing an estrogen replacement therapy in young adult women with Turner syndrome